Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01370148 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
A Phase 1 study, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT01370148 is a Phase 1 study that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 17 participants.
The verdict
NCT01370148, a Phase 1 study, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the pharmacokinetics and safety of a 48-hour continuous infusion of conivaptan in subjects with severe liver impairment compared to subjects with normal liver function.
Interventions
- DRUG conivaptan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01370148
The ClinicalTrials.gov registry entry for NCT01370148 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which conivaptan hydrochloride is the first listed.
NCT01370148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01370148 about?
NCT01370148 is a clinical study titled "A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan". The purpose of this study is to assess the pharmacokinetics and safety of a 48-hour continuous infusion of conivaptan in subjects with severe liver impairment compared to subjects with normal liver function.
What is the current status of trial NCT01370148?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2011-04. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01370148?
The interventions under investigation include: conivaptan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01370148?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.